<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414566</url>
  </required_header>
  <id_info>
    <org_study_id>2020HXFH037</org_study_id>
    <nct_id>NCT04414566</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Induction Chemotherapy Plus Radiotherapy Alone Versus Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare induction chemotherapy (TPF or GP) plus radiotherapy
      alone with induction chemotherapy plus concurrent chemoradiotherapy in patients with
      locoregionally advanced nasopharyngeal carcinoma (LA-NPC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Disease-free survival rate is calculated from the date of randomization to the date of treatment failure or death from any cause, whichever is first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional recurrence-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Locoregional recurrence-free survival is calculated from randomization to the first locoregional recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Distant metastasis-free survival is calculated from randomization to the first remote metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rates after treatments</measure>
    <time_frame>At the end of Cycle 3 of induction chemotherapy (each cycle is 21 days) and 16 weeks after completion of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Every week during treatment, up to 4 weeks after treatment.</time_frame>
    <description>Incidence of acute toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">562</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IC plus RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC plus CCRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil</intervention_name>
    <description>Patients receive GP gemcitabine (1000 mg/m^2 d1,8) and cisplatin (80mg/m^2 d1) or TPF docetaxel (60mg/m^2 on day 1), cisplatin (60mg/m^2 on day 1) and fluorouracil (600mg/m^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.</description>
    <arm_group_label>IC plus CCRT</arm_group_label>
    <arm_group_label>IC plus RT</arm_group_label>
    <other_name>GP;TPF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.</description>
    <arm_group_label>IC plus RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT and concurrent cisplatin</intervention_name>
    <description>Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m^2 every 3 weeks for 3 cycles.</description>
    <arm_group_label>IC plus CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly pathologically confirmed as non-keratinizing nasopharyngeal carcinoma
             (differentiated or undifferentiated, ie WHO type II or III).

          -  Age ≥ 18 and ≤ 65 years old.

          -  Tumor staged as III/IVa (according to the 8th AJCC edition).

          -  No evidence of distant metastasis (M0).

          -  Satisfactory performance status: Karnofsky scale (KPS) ≥ 70.

          -  Adequate marrow: White blood cells (WBC) ≥ 4 × 10^9/L, hemoglobin (HGB) ≥ 90 g/L,
             platelets (PLT) ≥ 100 × 10^9/L (or within the normal range of the laboratory)

          -  Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase
             (AST) &lt; 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤
             2.5×ULN, and bilirubin ≤ ULN.

          -  Adequate renal function: creatinine clearance ≥ 60 ml/min.

          -  Written informed consent.

        Exclusion Criteria:

          -  WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.

          -  Age &gt; 65 or &lt; 18.

          -  Treatment with palliative intent.

          -  Previous history of malignant tumors, well-treated basal cell carcinoma or squamous
             cell carcinoma and cervical carcinoma in situ outer.

          -  Pregnancy or lactation.

          -  History of previous RT (except for non-melanomatous skin cancers outside intended RT
             treatment volume), chemotherapy or surgery (except diagnostic) to primary tumor or
             nodes.

          -  Any other serious diseases, which may bring greater risk or affect the compliance of
             the test, for example, unstable cardiac disease requiring treatment, renal disease,
             chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt; 1.5×ULN), and
             emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingchen Peng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingchen Peng, MD, PhD</last_name>
    <phone>+86 18980606753</phone>
    <email>pxx2014@scu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xingchen Peng</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 24, 2020</study_first_submitted>
  <study_first_submitted_qc>May 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xingchen Peng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

